{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=67",
    "query": {
      "intervention": "Cohorting",
      "page": 67
    },
    "page_size": 10
  },
  "pagination": {
    "page": 67,
    "page_size": 10,
    "total_count": 11377,
    "total_pages": 1138,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=68&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=66&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T03:08:14.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04128579",
      "title": "Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Erythematosus",
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Itolizumab [Bmab 600]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biocon Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 52,
      "start_date": "2019-10-01",
      "completion_date": "2024-01-18",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 19,
      "location_summary": "Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04128579"
    },
    {
      "nct_id": "NCT07659379",
      "title": "Gotistobart Long Term Extension (LTE) Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Gotistobart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoC4, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-07-28",
      "completion_date": "2037-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 2,
      "location_summary": "Fort Worth, Texas • Tyler, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07659379"
    },
    {
      "nct_id": "NCT02028403",
      "title": "Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BMS-936559",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-936559",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2014-06",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02028403"
    },
    {
      "nct_id": "NCT02143466",
      "title": "AZD9291 in Combination With Ascending Doses of Novel Therapeutics",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Part A - AZD9291 in combination with AZD6094",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with intermittent selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with MEDI4736",
          "type": "DRUG"
        },
        {
          "name": "Part B - AZD9291 in combination with AZD6094",
          "type": "DRUG"
        },
        {
          "name": "Part B - AZD9291 in combination with selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Part B - AZD9291 in combination with MEDI4736",
          "type": "DRUG"
        },
        {
          "name": "Part C - AZD6094 monotherapy (Japan only)",
          "type": "DRUG"
        },
        {
          "name": "Part C - AZD9291 in combination with AZD6094 (Japan only)",
          "type": "DRUG"
        },
        {
          "name": "Part D - AZD9291 in combination with AZD6094",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 344,
      "start_date": "2014-08-05",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143466"
    },
    {
      "nct_id": "NCT02380677",
      "title": "Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor Malignancy"
      ],
      "interventions": [
        {
          "name": "CRLX301",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewLink Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2015-04",
      "completion_date": "2017-10-04",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 3,
      "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02380677"
    },
    {
      "nct_id": "NCT02910557",
      "title": "Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma",
        "Herpetic Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 187,
      "start_date": "2017-08-10",
      "completion_date": "2026-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 9,
      "location_summary": "Coral Springs, Florida • Baltimore, Maryland • Jefferson City, Missouri + 5 more",
      "locations": [
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Jefferson City",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02910557"
    },
    {
      "nct_id": "NCT06414603",
      "title": "A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Transplant Failure and Rejection"
      ],
      "interventions": [
        {
          "name": "The Prospera™ Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Natera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-06-10",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06414603"
    },
    {
      "nct_id": "NCT05889286",
      "title": "F18-MHF: Implants-Associated Infection Detection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Knee Disease",
        "Knee Infection"
      ],
      "interventions": [
        {
          "name": "[F-18]MHF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-11-04",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05889286"
    },
    {
      "nct_id": "NCT02085473",
      "title": "A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Healthy Subjects or Volunteers"
      ],
      "interventions": [
        {
          "name": "Tralokinumab 300 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-03-19",
      "completion_date": "2014-07-10",
      "has_results": true,
      "last_update_posted_date": "2018-12-31",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 2,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02085473"
    },
    {
      "nct_id": "NCT07284654",
      "title": "Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Disease"
      ],
      "interventions": [
        {
          "name": "31 valent pneumococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV21",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxcyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4049,
      "start_date": "2025-12-01",
      "completion_date": "2026-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-01T03:08:14.693Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chinle",
          "state": "Arizona"
        },
        {
          "city": "Whiteriver",
          "state": "Arizona"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07284654"
    }
  ]
}